These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22830621)

  • 1. Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells.
    Knoepfler PS
    Regen Med; 2012 Sep; 7(5):713-20. PubMed ID: 22830621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roadblocks en route to the clinical application of induced pluripotent stem cells.
    Lowry WE; Quan WL
    J Cell Sci; 2010 Mar; 123(Pt 5):643-51. PubMed ID: 20164303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hurdles to clinical translation of human induced pluripotent stem cells.
    Neofytou E; O'Brien CG; Couture LA; Wu JC
    J Clin Invest; 2015 Jul; 125(7):2551-7. PubMed ID: 26132109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells.
    Narsinh KH; Sun N; Sanchez-Freire V; Lee AS; Almeida P; Hu S; Jan T; Wilson KD; Leong D; Rosenberg J; Yao M; Robbins RC; Wu JC
    J Clin Invest; 2011 Mar; 121(3):1217-21. PubMed ID: 21317531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells.
    Ghosh Z; Wilson KD; Wu Y; Hu S; Quertermous T; Wu JC
    PLoS One; 2010 Feb; 5(2):e8975. PubMed ID: 20126639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hope for regenerative treatments: toward safe transplantation of human pluripotent stem-cell-based therapies.
    Kimbrel EA; Lanza R
    Regen Med; 2015; 10(2):99-102. PubMed ID: 25835474
    [No Abstract]   [Full Text] [Related]  

  • 8. The translational potential of human induced pluripotent stem cells for clinical neurology : The translational potential of hiPSCs in neurology.
    Devine H; Patani R
    Cell Biol Toxicol; 2017 Apr; 33(2):129-144. PubMed ID: 27915387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Who Will Win: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells for β Cell Replacement and Diabetes Disease Modeling?
    Jacobson EF; Tzanakakis ES
    Curr Diab Rep; 2018 Oct; 18(12):133. PubMed ID: 30343423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10 Questions: Clinical Outlook for iPSCs.
    Cell Stem Cell Editorial Team
    Cell Stem Cell; 2016 Feb; 18(2):170-3. PubMed ID: 26849303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The moral value of induced pluripotent stem cells: a Japanese bioethics perspective on human embryo research.
    Sawai T
    J Med Ethics; 2014 Nov; 40(11):766-9. PubMed ID: 24951671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do we still need human embryonic stem cells for stem cell-based therapies? Epistemic and ethical aspects.
    Hug K; Hermerén G
    Stem Cell Rev Rep; 2011 Nov; 7(4):761-74. PubMed ID: 21461713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem Cell Therapy and Immunological Rejection in Animal Models.
    Jin X; Lin T; Xu Y
    Curr Mol Pharmacol; 2016; 9(4):284-288. PubMed ID: 26415913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory insight into the European human pluripotent stem cell registry.
    Kurtz A; Stacey G; Kidane L; Seriola A; Stachelscheid H; Veiga A
    Stem Cells Dev; 2014 Dec; 23 Suppl 1(Suppl 1):51-5. PubMed ID: 25457963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation dynamics in human induced pluripotent stem cells.
    Nishino K; Umezawa A
    Hum Cell; 2016 Jul; 29(3):97-100. PubMed ID: 27083573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From embryonic stem cells to induced pluripotent stem cells-Ready for clinical therapy?
    Hu J; Wang J
    Clin Transplant; 2019 Jun; 33(6):e13573. PubMed ID: 31013374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will SCNT-ESCs be better than iPSCs for personalized regenerative medicine?
    Sancho-Martinez I; Izpisua Belmonte JC
    Cell Stem Cell; 2013 Aug; 13(2):141-2. PubMed ID: 23910080
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression.
    Uosaki H; Fukushima H; Takeuchi A; Matsuoka S; Nakatsuji N; Yamanaka S; Yamashita JK
    PLoS One; 2011; 6(8):e23657. PubMed ID: 21876760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the optimal suspension culture time for the osteoblastic differentiation of human induced pluripotent stem cells using the embryoid body method.
    Zhou P; Han Y; Shi J; Zhang R; Ren X; Li H; Lan F
    Biochem Biophys Res Commun; 2019 Aug; 515(4):586-592. PubMed ID: 31178132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.